A Meta-Analysis of Treatment for Primary Sjögren's Syndrome.
The current focus of treatment in primary Sjögren's Syndrome (SS) is symptom management. Since this is an autoimmune disease with multi-system involvement, there may be a role for systemic immunosuppression to improve signs and symptoms and prevent progression. Five electronic databases (MEDLINE, EMBASE, CENTRAL, CLINICALTRIALS.GOV, WHO ICTRP) were searched to include randomized controlled trials (RCTs) for the treatment of SS. Primary outcome measures included ocular dryness, oral dryness, tear production, salivary function; Serious adverse events (AEs) and withdrawals due to AEs were also assessed. The searched yielded 32 trials evaluating 19 different medications. Average duration of diagnosis was long (up to 9.2 years). Twenty-two trials examined ocular and oral dryness, of which only 2 and 4 revealed statistically significant improvements respectively. No studies found benefit for tear production; Few studies found improvements for unstimulated (3/16 RCTs) and stimulated salivary flow (2/14 RCTs). Meta-analysis at 6 months found improvements as compared to placebo for unstimulated salivary flow (p=0.003) and decrease in ESR (p=0.007). No differences were seen for serious AEs but there were increased withdrawals from AEs (RR 2.33; p=0.03). Reducing inflammation potentially improves salivary gland function. No individual immunomodulatory drug demonstrated consistent benefit in xerostomia and xerophthalmia. Further work is needed to identify SS patients with ability to improve and outcomes that are valid and sensitive to change within clinical trials. Trade offs in future between benefit and safety may also be important as more withdrawals occurred with active treatment. This article is protected by copyright. All rights reserved.